Prothena Corporation

Prothena Corporation Assets per Share

The Total Assets per Share of Prothena Corporation (PRTA) as of Oct 8, 2026 is 6.07 USD. In the previous year, Total Assets per Share was 10.16 USD — a change of -40.27% (lower).

Assets per Share

6.07USD

YoY

-40.27%

Last updated:

Total Assets per Share of Prothena Corporation is 2025 6.07 USD. Total Assets per Share of Prothena Corporation was 2024 10.16 USD. It decreases by -40.27% lower compared to the previous year.

The Prothena Corporation Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
9.27 USD
Jan 1, 2019
7.79 USD
Jan 1, 2020
6.19 USD
Jan 1, 2021
11.32 USD
Jan 1, 2022
14.08 USD
Jan 1, 2023
12.94 USD
Jan 1, 2024
10.16 USD
Jan 1, 2025
6.07 USD
The Prothena Corporation Assets per Share history
YEARAssets per ShareYoY
6.07USD-40.27%
10.16USD-21.44%
12.94USD-8.13%
14.08USD+24.40%
11.32USD+83.01%
6.19USD-20.58%
7.79USD-15.94%
9.27USD+0.50%
9.22USD+7.90%
8.55USD+19.40%
7.16USD+26.67%
5.65USD—
Access this data via the Eulerpool API

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prothena Corporation stock

Total Assets per Share of Prothena Corporation is 6.07 USD in 2025.

Total Assets per Share of Prothena Corporation changed from 10.16 USD to 6.07 USD, representing a -40.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

Other — Prothena Corporation

All Key Metrics — Prothena Corporation